臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :2856565
	造訪人次 : 53437446 線上人數 : 815 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hung c c"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 191-200 / 1701 (共171頁)
<< < 15 16 17 18 19 20 21 22 23 24 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-09-04T06:12:42Z	Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy	Sheng W.-H.; Hung C.-C.; Wu R.-J.; Wang J.-T.; Chen P.-J.; Chang S.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T06:12:40Z	Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: A matched cohort study	Sheng W.-H.; Hung C.-C.; JIA-HORNG KAO; Chang S.-Y.; Chen M.-Y.; Hsieh S.-M.; Chen P.-J.; Chang S.-C.
臺大學術典藏	2021-09-04T06:11:58Z	Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy	Sheng W.-H.; Hung C.-C.; Chang S.-Y.; Liu C.-J.; Chen M.-Y.; Hsieh S.-M.; JIA-HORNG KAO; Chen P.-J.; Chang S.-C.
臺大學術典藏	2021-09-04T06:11:21Z	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study	Liu C.-H.; Sheng W.-H.; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:06Z	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection	Liu C.-H.; Sun H.-Y.; Liu C.-J.; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:17:00Z	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study	Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:40Z	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan	Liu C.-H.; Liu C.-J.; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏	2021-09-04T05:16:17Z	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan	Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; Liu C.-J.; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; JIA-HORNG KAO
臺大學術典藏	2021-09-02T00:04:05Z	Improved design and in vivo animal tests of bone-guided cochlear implant microsystem with monopolar biphasic multiple stimulation and neural action potential acquisition	Wang S.-H;Huang Y.-K;Chen C.-Y;Lee C.-F;Yang C.-H;Hung C.-C;Liu C.-H;Ker M.-D;Wu C.-Y.; Wang S.-H; Huang Y.-K; Chen C.-Y; Lee C.-F; Yang C.-H; Hung C.-C; Liu C.-H; Ker M.-D; Wu C.-Y.; CHIA-HSIANG YANG
臺大學術典藏	2021-08-27T06:48:57Z	Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor	KUAN-YIN LIN; Cheng C.-Y.; Yang C.-J.; Tsai M.-S.; Hsieh S.-M.; Sun H.-Y.; Sheng W.-H.; Chen M.-Y.; Chang S.-Y.; Cheng S.-H.; Hung C.-C.

顯示項目 191-200 / 1701 (共171頁)
<< < 15 16 17 18 19 20 21 22 23 24 > >>
每頁顯示[10|25|50]項目